During the past decade, Cancer Institute and Hospital, Chinese Academy of Medical Sciences conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 11 clinical trials were completed, i.e. on average, 15.7% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 5 clinical trials were completed. i.e. 22.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" #1 sponsor was "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 45 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 16 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 10 trials sponsored, "Pfizer" with 8 trials sponsored and "Qilu Pharmaceutical Co., Ltd." with 8 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" #1 collaborator was "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 16 trials as a collaborator, "Peking University Cancer Hospital & Institute" with 6 trials as a collaborator, "Tianjin Medical University Cancer Institute and Hospital" with 5 trials as a collaborator, "China-Japan Friendship Hospital" with 4 trials as a collaborator and "Zhejiang Cancer Hospital" with 4 trials as a collaborator. Other collaborators include 63 different institutions and companies that were collaborators in the rest 64 trials.

According to Clinical.Site data, the most researched conditions in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" are "Breast Cancer" (16 trials), "Colorectal Cancer" (6 trials), "Hepatocellular Carcinoma" (5 trials), "Metastatic Breast Cancer" (5 trials) and "Advanced Cancer" (4 trials). Many other conditions were trialed in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" in a lesser frequency.

Most popular intervention types in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" are "Drug" (94 trials), "Radiation" (10 trials), "Procedure" (5 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Anlotinib" (14 trials), "Placebo" (7 trials), "Letrozole" (4 trials), "capecitabine" (4 trials) and "Capecitabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" are 93 trials for "All" genders, 23 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 29 active trials in "Cancer Institute and Hospital, Chinese Academy of Medical Sciences". 2 are not yet recruiting, 17 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in Cancer Institute and Hospital, Chinese Academy of Medical Sciences, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Cancer Institute and Hospital, Chinese Academy of Medical Sciences, 28 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".